ArticleBMC cancer2025
Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antileukemic Activity ofMolecules (Basel, Switzerland) · 2026Article
- Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic Myeloid Leukemia (CML) is characterized by the BCR-ABL fusion gene, which encodes the tyrosine kinase of BCR-ABL. Developing tyrosine kinase inhibitors (TKIs) can specifically inhibit the BCR-ABL oncoprotein and cure CML. However, problems such as drug resistance to this targeted therapy make for therapeutic failure and relapse. This study investigated the expression of histone deacetylase 8 (HDAC8), Sirtuin 1 (SIRT1), and P53 genes with drug resistance in chronic myeloid leukemia patients.
methodsIn this study, 50 CML patients were divided into two groups: drug-resistant and drug-sensitive patients, and 50 healthy individuals were included as controls. After extracting RNA from the blood samples and quality assessment, cDNA was synthesized, and then a real-time polymerase chain reaction (Real-Time PCR) method was performed to check the expression of HDAC8, SIRT1, and P53 genes. Finally, statistical analysis was performed using SPSS version 25 and Stata software.
resultsThe expression of the SIRT1 gene in drug-resistant patients was significantly higher than in CML patients who were drug-sensitive and also in the control group (p < 0.001). Our results showed a lower value of ΔCT for the p53 gene than the SIRT1 gene in drug-resistant patients. However, p53 gene expression was not significantly different between drug-sensitive and drug-resistant groups (p = 0.593). We observed that CML patients had significantly higher expression of the HDAC8 gene than the control subjects (p < 0.001).
conclusionOur results suggested a probable association between perturbations of SIRT1, HDAC8, and P53 gene expression with the pathogenesis of CML. Also, SIRT1 and HDAC8 gene expression might have regulatory roles in optimal response to targeted therapy in CML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.